References
- Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood 2017;130:1800-8
- Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med 2017;377:2531-44
- Othus M, Bansal A, Koepl L, et al. Accounting for cured patients in cost-effectiveness analysis. Value Health 2017;20:705-9
- Arias E, Heron M, Xu JQ. United States life tables, 2014. National vital statistics reports; vol66 no 4. Hyattsville, MD: National Center for Health Statistics; 2017
- Gold MR, Siegel JE, Russell LB, et al. Cost-effectiveness in health and medicine. New York: Oxford University Press; 1996
- Minacori R, Bonastre J, Lueza B, et al. How to model survival in cost-effectiveness analysis? Differences between Markov and partitioned survival analysis models. Value Health 2015;18:A704
- Akaike H. A new look at the statistical model identification. IEEE Trans Auto Contr 1974;19:716-23
- Coiffier B, Thieblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d’Etudes des Lymphomes de l’Adulte. Blood 2010;116:2040-5
- Howlader N, Mariotto AB, Besson C, et al. Cancer-specific mortality, cure fraction, and noncancer causes of death among diffuse large B-cell lymphoma patients in the immunochemotherapy era. Cancer 2017;123:3326-34
- Bansal A, Lin V, Sullivan SD, et al. Estimating long-term survival for patients with relapsed or refractory aggressive non-Hodgkin lymphoma treated with anti-CD19 chimeric antigen receptor T-Cell therapy: A comparison of standard and mixture cure models. Biol Blood Marrow Transplant. 2018;24(3):S310
- Neelapu SS, Locke FL, Bartlett NL, et al. Long-term follow-up ZUMA-1: A pivotal trial of axicabtagene ciloleucel (Axi-Cel; KTE-C19) in patients with refractory aggressive non-Hodgkin lymphoma (NHL). Blood. 2017;130(Suppl 1):578-578.
- Agency for Healthcare Research and Quality. Healthcare utilization project. Rockville, MD; 2018. Available at: https://www.hcup-us.ahrq.gov/overview.jsp [Last accessed February 9, 2017]
- Pelletier EM, Smith PJ, Dembek CJ. Payer costs of autologous stem cell transplant: results from a U.S. claims data analysis. Blood 2008;112:2373
- Mariotto AB, Yabroff KR, Shao Y, et al. Projections of the cost of cancer care in the United States: 2010–2020. J Natl Cancer Inst 2011;103:117-28
- Sanders GD, Neumann PJ, Basu A, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA 2016;316:1093-103
- Centers for Medicare & Medicaid Services, Office of the Actuary. National health statistic expenditure data: health expenditures by state of residence.Baltimore, MD: Center for Medicare & Medicaid Services; 2017. Available at: https://www.cms.gov/Research-Systems/Statistics-Trends-and-Reports/NationalHealthExpendData/NationalHealthAccountsStateHealthAc [Last accessed May 3, 2018]
- Agency for Healthcare Research and Quality. Healthcare utilization project. 2015 Healthcare Cost and Utilization Report. Washington, DC; 2015. Available at: http://www.healthcostinstitute.org/files/2015 HCCUR_2.pdf [Last accessed May 3, 2018]
- Lin VW, Jiang Y, Chuang LH, et al. Health utilities for patients with relapsed or refractory large B-cell lymphoma: ad hoc analysis from an axicabtagene ciloleucel safety management study. 44th Annual Meeting of the European Society for Blood and Marrow Transplantation; Lisbon, Portugal, March 20, 2018
- Sullivan PW, Ghushchyan V. Preference-based EQ-5D index scores for chronic conditions in the United States. Med Decis Making 2006;26:410-20
- Huntington SF, Svoboda J, Doshi JA. Cost-effectiveness analysis of routine surveillance imaging of patients with diffuse large B-cell lymphoma in first remission. J Clin Oncol 2015;33:1467-74
- Chen Q, Staton AD, Ayer T, et al. Exploring the potential cost-effectiveness of precision medicine treatment strategies for diffuse large B-cell lymphoma. Leuk Lymph 2018;59(7):1700-1709.
- Best JH, Hornberger J, Proctor SJ, et al. Cost-effectiveness analysis of rituximab combined with chop for treatment of diffuse large B-cell lymphoma. Value Health 2005;8:462-70
- Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness—the curious resilience of the $50,000-per-QALY threshold. N Engl J Med 2014;371:796-7
- Nadler E, Eckert B, Neumann PJ. Do oncologists believe new cancer drugs offer good value? Oncologist 2006;11:90-5
- Berry SR, Bell CM, Ubel PA, et al. Continental divide? The attitudes of US and Canadian oncologists on the costs, cost-effectiveness, and health policies associated with new cancer drugs. J Clin Oncol 2010;28:4149-53
- Neumann PJ, Palmer JA, Nadler E, et al. Cancer therapy costs influence treatment: a national survey of oncologists. Health Aff (Millwood) 2010;29:196-202
- Greenberg D, Earle C, Fang CH, et al. When is cancer care cost-effective? A systematic overview of cost-utility analyses in oncology. J Natl Cancer Inst 2010;102:82-8
- Institute for Clinical and Economic Review (ICER). Chimeric antigen receptor T-cell therapy for B-cell cancers: effectiveness and value. Final Evidence Report. Boston, MA: ICER; 2018. Available at: https://icer-review.org/wp-content/uploads/2017/07/ICER_CAR_T_Final_Evidence_Report_032318.pdf [Last accessed April 27, 2018]
- Othus M, Barlogie B, LeBlanc ML, et al. Cure models as a useful statistical tool for analyzing survival. Clin Cancer Res 2012;18:3731-6
- Lambert PC, Thompson JR, Weston CL, et al. Estimating and modeling the cure fraction in population-based cancer survival analysis. Biostatistics 2007;8:576-94
- Yu B, Tiwari RC, Cronin KA, et al. Cure fraction estimation from the mixture cure models for grouped survival data. Stat Med 2004;23:1733-47
- Othus M, Li Y, Tiwari RC. A class of semiparametric mixture cure survival models with dependent censoring. J Am Stat Assoc 2009;104:1241-50
- Kochenderfer JN, Somerville RPT, Lu T, et al. Long-duration complete remissions of diffuse large B cell lymphoma after anti-CD19 chimeric antigen receptor T cell therapy. Mol Ther 2017;25:2245-53
- Kutikova L, Bowman L, Chang S, Long SR, Arning M, Crown WH. Medical costs associated with non-Hodgkin's lymphoma in the United States during the first two years of treatment. Leukemia & Lymphoma. 2006;47(8):1535-1544
- Centers for Medicare and Medicaid Services. Medicare fee schedule. Available at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/FeeScheduleGenInfo/index.html. [Last accessed October 7, 2018]
- Kaiser Family Foundation. Hospital adjusted expenses per inpatient day. Available at: https://www.kff.org/health-costs/state-indicator/expenses-per-inpatient-day/?currentTimeframe=0&sortModel=%7B%22colId%22:%22Location%22,%22sort%22:%22asc%22%7D [Last accessed October 7, 2018]
- Dasta JF, McLaughlin TP, Mody SH, Piech CT. Daily cost of an intensive care unit day: the contribution of mechanical ventilation. Crit Care Med. 2005;33(6):1266-1271
- Centers for Medicare & Medicaid Services, Office of the Actuary. National health statistic expenditure data: health expenditures by state of residence. Available at: https://www.cms.gov/Research-Systems/Statistics-Trends-and-Reports/NationalHealthExpendData/NationalHealthAccountsStateHealthAc [Last accessed October 7, 2018]